Arix Bioscience says portfolio company Autolus to start study on leukaemia lead candidate
Arix said the clinical study will suffer “minimal” impact from the coronavirus outbreak
Company
Arix Bioscience PLC
LON:ARIX
Arix Bioscience is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting edge advances in life sciences. The company collaborates with exceptional entrepreneurs and provide the capital, expertise and global networks needed to help accelerate their ideas into important new treatments for patients. As a listed company, it aims to bring this growth phase of the industry to a broader range of investors.
180 stories · page 3 of 9
Arix Bioscience shuffles board, names Naseem Amin as executive chairman with immediate effect
Amin, who joined the Arix board in December 2019, has broad life sciences experience in both the US and Europe, having held senior positions in major healthcare businesses in R&D, business development, marketing, and in venture capital
Arix Bioscience to invest US$3.0mln in IPO by portfolio company, Imara Inc to retain 9.4% stake
Imara has priced its Nasdaq IPO of 4,700,000 shares of common stock at a public offering price of US$16.00 per share for aggregate gross proceeds of $75.2mln
Arix Bioscience focuses on “driving realisable value” after volatile year for markets
The firm exited 2019 in a strong financial position with some £55mln in the bank
Arix appoints entrepreneur in residence to source European investment opportunities
Iacone previously served as director and global head of the Rare Diseases Research division at Swiss pharma giant Roche
Arix Biosciences portfolio company Aura encouraged by trial results of eye cancer treatment
Tumour control and vision preservation data continue to be supportive of the planned Phase 3 registration trial in the second half of 2020
Arix Bioscience reveals one of its portfolio companies, Imara Inc. has applied to list on Nasdaq
Imara is a clinical-stage biotechnology company focused on developing new medicines to treat patients suffering from rare inherited genetic disorders of haemoglobin
Arix Bioscience investee company Autolus publishes encouraging additional data from blood cancer drug study
The updated data continue to support “early indications of durability and high level of activity previously reported”, Autolus said
Arix Bioscience says company co-founded in 2018 completed Series A financing, bringing total committed funding to $50mln
It teamed up with US venture capital group Atlas Venture to create pre-clinical stage firm Quench Bio, which is working on the first anti-inflammatory and autoimmune drugs targeting a protein called Gasdermin D
Arix Bioscience says portfolio company Autolus Therapeutics prices shares at US$11 each
In total it has put up for sale 7.25mln American Depositary Shares that will bring in a ‘gross’ US$80mln
Arix Bioscience appoints industry heavyweight to board
Amin has 25 years experience and is currently chief executive at GMP-Orphan and venture partner at Advent Life Sciences
Arix Bioscience notes portfolio company Iterum releases topline results for a Phase 3 trial of novel antibiotic, sulopenenem
Iterum said the full body of evidence from the trial, known as Sulopenem for Resistant Enterobacteriaceae (SURE) 3, confirms overall safety profile
Arix Bioscience hails promising results from Autolus' T-cell cancer therapy trials
Autolus now plans to advance toward a pivotal clinical trial in acute lymphoblastic leukemia, with initiation targeted for the first half of 2020
Roth repeats Buy rating on Arix Bioscience's portfolio company Harpoon Therapeutics
The Buy rating comes after Harpoon granted phama giant Abbvie an exclusive option over the rights to a treatment for a type of blood cancer
Arix Bioscience portfolio company Harpoon agrees US$2.4bn deal with Abbvie
For each of the targets, Harpoon will receive a milestone payment of $310mln each upfront plus royalties on global sales.
Arix Bioscience investee company strengthens pipeline
The venture capital firm applauded the exclusive deal inked by Artios Pharma
Arix Bioscience has “multiple shots on goal”, ShoreCap initiates as a ‘buy’
The stockbroker highlights that with 12 core investments there are multiple chances in the portfolio for success.
Arix Bioscience flags “signs of efficacy” at Aura eye cancer trial
“If approved, AU-011 represents the first potential new treatment for choroidal melanoma in several decades”
Jefferies puts 229p target on Arix Bioscience
“The current 31% discount is cheap in our view and allows no value for Arix's private assets,” the broker said
Arix Bioscience leads €20mln investment round that strengthens position in oncology
New investee company STipe Therapeutics is working on harnessing the immune response to target a range of tumours